29 results on '"Quintino S"'
Search Results
2. Uranium determination at ppb levels by X-ray fluorescence after its preconcentration on polyurethane foam
- Author
-
Marcelo Souza de Carvalho, José Luiz Mantovano, Maria de Lourdes F. Domingues, and Euclides Quintino S Filho
- Subjects
Detection limit ,Aqueous solution ,Filter paper ,chemistry.chemical_element ,X-ray fluorescence ,Uranium ,Atomic and Molecular Physics, and Optics ,Analytical Chemistry ,chemistry ,Wastewater ,Seawater ,Solid phase extraction ,Instrumentation ,Spectroscopy ,Nuclear chemistry - Abstract
A sensitive method based on the preconcentration of uranium on powdered polyurethane foam (PUF) has been developed to determinate this element in water samples by X-ray florescence. Uranium at ppb levels was sorbed as the salicylate complex on powdered PUF at pH 4.0. The resulting PUF was filtered through a filter paper and used for X-ray fluorescence measurements. For 50 μg/l of uranium the coefficient of variation for five measurements is 5% and the detection limit is 5.5 μg/l. The interference level of various ions and ligands was studied and optimum conditions were developed to determine uranium in reference materials, waste water, mine drainage, and sea water.
- Published
- 1998
3. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with Imatinib mesylate
- Author
-
Fugazza, Giuseppina, Miglino, Maurizio, Bruzzone, Roberto, Quintino, S., Gatti, A. M., Grasso, R., Frassoni, F., and Gobbi, Marco
- Published
- 2004
4. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
- Author
-
Clavio, M., Quintino, S., Venturino, C., Filippo Ballerini, Varaldo, R., Gatto, S., Galbusera, V., Garrone, A., Grasso, R., Canepa, L., Miglino, M., Pierri, I., and Gobbi, M.
- Published
- 2001
5. Thalidomide in agnogenic and secondary myelofibrosis
- Author
-
Canepa, L., Ballerini, F., Varaldo, R., Quintino, S., Reni, L., Clavio, M., Miglino, Maurizio, Pierri, Ivana, and Gobbi, Marco
- Published
- 2001
6. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens
- Author
-
Clavio, M, Quintino, S, Masoudi, B, Carrara, S, Cerri, R, Pierri, Ivana, Canepa, L, Miglino, Maurizio, Muner, P, Damasio, E, and Gobbi, Marco
- Published
- 2001
7. Uranium determination at ppb levels by X-ray fluorescence after its preconcentration on polyurethane foam
- Author
-
Carvalho, Marcelo S, primary, Domingues, Maria de Lourdes F, additional, Mantovano, José L, additional, and Filho, Euclides Quintino S, additional
- Published
- 1998
- Full Text
- View/download PDF
8. Redox method for the determination of stability constants of some trivalent metal complexes
- Author
-
Delgado, R., Figueira, M. C., and Quintino, S.
- Published
- 1997
- Full Text
- View/download PDF
9. Milho safrinha consorciado com Braquiária sob plantio direto no Sudoeste da Amazônia brasileira, análise de eficiência econômica, safra 2017/2018
- Author
-
QUINTINO, S. M., RIBEIRO, R. da S., PASSOS, A. M. A. dos, Simone Marçal Quintino, Universidade Federal de Rondônia, Rodrigo da Silva Ribeiro, Universidade Federal de Rondônia, and ALEXANDRE MARTINS ABDAO DOS PASSOS, CNPMS.
- Subjects
ILP ,Integração-Lavoura-Pecuária ,Sustentabilidade ,Agricultura Sustentável ,Consorciação de Cultura - Abstract
O planejamento e o controle dos custos de produção são fundamentais para que o produtor rural obtenha retornos satisfatórios e o auxilie nas tomadas de decisão. Objetivou-se realizar uma análise econômica da atividade de milho safrinha em sistema plantio direto, consorciado com a braquiária, na região norte no estado de Rondônia, na cidade de Porto Velho, safra 2017/2018. Para a obtenção dos custos, aplicou-se a multiplicação da matriz de coeficientes técnicos pelo vetor de preços dos fatores para a safra 2017/2018. Os valores utilizados para a formação dos custos totais e variáveis de produção e análise de indicadores de eficiência financeira e econômica foram os observados na região de Porto Velho em fevereiro de 2018 (custo) e agosto de 2018 (receita). O custo total foi estimado em R$ 2.377,18 ha-1. Dentre os insumos, o fertilizante foi o item mais elevado, correspondendo a 35,3% do custo total, seguido das sementes de milho, com 17,9%. O ponto de nivelamento para o milho foi estimado em 70,33 sc ha-1. A Relação Benefício Custo (B/C) foi favorável de 1,05. A Margem de Contribuição obtida foi positiva com valor de R$ 254,36. Conclui-se que a cultura do milho foi suficiente para pagar a atividade e a formação de pasto para o período de entressafra. O cultivo do milho em sucessão à soja safra em condições de plantio direto, mostrou-se economicamente viável, mesmo com margem mínima de lucratividade. Made available in DSpace on 2019-12-12T18:19:01Z (GMT). No. of bitstreams: 1 Milhosafrinha.pdf: 212223 bytes, checksum: a03f710ca14143c6dbc939d72096f0ac (MD5) Previous issue date: 2019
10. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly
- Author
-
Pierri, I., Clavio, M., Beltrami, G., Cavaliere, M., Lanza, L., Miglino, M., Canepa, L., Pietrasanta, D., Filippo Ballerini, Quintino, S., Gatto, S., Celesti, L., Carrara, P., Varese, P., and Gobbi, M.
11. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for De Novo AML patients
- Author
-
Clavio, M., Gatto, S., Beltrami, G., Quintino, S., Canepa, L., Pierri, I., Galbusera, V., Carrara, P., Miglino, M., Riccardo Varaldo, Ballerini, F., Venturino, C., Cerri, R., Risso, M., Balleari, E., Carella, A. M., Sessarego, M., Ghio, R., Bacigalupo, A., and Gobbi, M.
- Subjects
Adult ,Myeloid ,Male ,Adolescent ,Acute ,Antineoplastic Combined Chemotherapy Protocols ,drug therapy/genetics/therapy ,administration /&/ dosage/analogs /&/ derivatives ,Humans ,administration /&/ dosage ,Retrospective Studies ,Recombinant ,Leukemia ,Patient Selection ,Cytarabine ,Middle Aged ,Combined Modality Therapy ,Survival Analysis ,adverse effects/therapeutic use ,drug therapy/genetics/mortality/therapy ,Treatment Outcome ,Granulocyte Colony Stimulating Factor ,Karyotyping ,Myelodysplastic Syndromes ,Female ,Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols ,adverse effects/therapeutic use, Combined Modality Therapy, Cytarabine ,administration /&/ dosage, Female, Granulocyte Colony Stimulating Factor ,adverse effects/therapeutic use, Humans, Idarubicin ,administration /&/ dosage, Karyotyping, Leukemia ,drug therapy/genetics/mortality/therapy, Male, Middle Aged, Myelodysplastic Syndromes ,drug therapy/genetics/therapy, Patient Selection, Retrospective Studies, Stem Cell Transplantation, Survival Analysis, Treatment Outcome, Vidarabine ,Idarubicin ,Vidarabine ,Stem Cell Transplantation
12. Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values
- Author
-
Valeria Pinto, Vincenzo Voi, Barbara Gianesin, Paola Corti, Maddalena Casale, Sabrina Quintino, Gian Luca Forni, Carmelo Fidone, Gianesin, B., Pinto, V. M., Casale, M., Corti, P., Fidone, C., Quintino, S., Voi, V., and Forni, G. L.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Thalassemia ,Hemoglobin, Sickle ,Reproducibility of Result ,Predictive Value of Test ,Disease ,Anemia, Sickle Cell ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Predictive Value of Tests ,Electrolyte imbalance ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Adverse effect ,Volumes exchanged ,Protocol (science) ,HbS% ,MEEX ,Blood Volume ,Blood Volume Determination ,business.industry ,Sickle cell disease ,Hb ,Reproducibility of Results ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Prospective Studie ,Hemoglobinopathy ,Italy ,030220 oncology & carcinogenesis ,Standard protocol ,Female ,Hemoglobin ,business ,Erythrocyte Transfusion ,030215 immunology ,Human - Abstract
Manual erythroexchange (MEEX) was proven to be effective and safe in the management of sickle cell disease (SCD). The goal is to quickly reduce the percentage of hemoglobin S (HbS%). A national survey of the Italian Society for Thalassemia and Hemoglobinopathies (SITE) observed a great variability among MEEX protocols none of which were found to be predictive of the values of HbS% and hemoglobin (Hb) after the exchange. Two equations to estimate the HbS% and Hb values to be obtained after MEEX were developed based on the results of the MEEX procedures in place in the centers participating in the present study. A standard protocol was subsequently defined to evaluate the volumes to exchange to obtain the target values of HbS% and Hb. The protocol was tested in 261 MEEX performed in SCD patients followed in the 5 participating centers that belong to the Italian Hemoglobinopathy Comprehensive Care Network, with the support of the SITE. The results showed a correlation between the estimated and measured values of HbS% and Hb (Rp 0.95 and 0.65 respectively, p < 0.001). A negligible bias was found for the prediction of HbS% and a bias of 1g/dl for Hb. From consecutive MEEX, a rate of increase of HbS% between two exchanges of around 0.4% per day (p < 0.001) was measured. This protocol was shown to be effective and safe, as all patients reached the target value of HbS%. All the MEEX procedures were carried out with single venous access. No adverse events or reactions such as hypotension or electrolyte imbalance were reported nor were any complaints concerning the procedures received from patients.
- Published
- 2020
13. Reduction of extramedullary erythropoiesis and amelioration of anemia in a β-thalassemia patient treated with thalidomide.
- Author
-
Pinto VM, Romano N, Balocco M, Carrara P, Lamagna M, Quintino S, Castaldi A, and Forni GL
- Subjects
- Humans, Thalidomide therapeutic use, Erythropoiesis, beta-Thalassemia complications, beta-Thalassemia drug therapy, Hematopoiesis, Extramedullary, Hematologic Diseases, alpha-Thalassemia
- Abstract
β-thalassemia patient treated with thalidomide: dimensional reduction of EMH foci (MRI evaluation) and reduction of hematological responce at follow-up., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
14. Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease.
- Author
-
Pinto VM, Gianesin B, Sardo S, Mazzi F, Baiardi G, Menotti S, Piras F, Quintino S, Robello G, Mattioli F, Finco G, Forni GL, and De Franceschi L
- Subjects
- Adult, Child, Humans, Ketorolac therapeutic use, Acute Pain drug therapy, Tramadol, Anemia, Sickle Cell complications, Anemia, Sickle Cell drug therapy, Hemoglobinopathies, Analgesia
- Abstract
Pain is an hallmark of sickle-cell-related acute clinical manifestations as part of acute vaso-occlusive crisis (VOC). In SCD pain has different origins such as vascular or neuropathic pain, which requires multimodal analgesia. This is based on the administration of drugs with different pharmacological mechanisms of action, maximizing analgesia and minimizing their adverse events and the risk of drug-addition in patients experiencing acute-recurrent pain events as in SCD. Ketorolac is a potent non-narcotic analgesic, being relatively safe and effective during pain-management in children and adults. Up to now, there is a lack of safety information on continuous infusion ketorolac as used to control acute pain in patients with SCD, and the benefits/risks ratio needs to be investigated. Here, we report for the first time the safety profile of ketorolac in the special population of patients with SCD. We confirmed that ketorolac in combination with tramadol, an opioid like molecule, is effective in pain control of adult patients with SCD experiencing acute severe VOCs defined by pain visual analog scale. Our study shows that short term (72 h) continuous infusion of ketorolac plus tramadol is not associated with adverse events such as liver or kidney acute disfunction or abnormalities in coagulation parameters during patients' hospitalization and within 30 days after patients discharge. This is extremely important for patients with SCD, who should have access to multimodal therapy to control recurrent acute pain crisis in order to limit central sensitization a fearsome issue of undertreated recurrent acute pain and of chronic pain., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. Coinheritance of PIEZO1 variants and multi-locus red blood cell defects account for the symptomatic phenotype in beta-thalassemia carriers.
- Author
-
Pinto VM, Russo R, Quintino S, Rosato BE, Marra R, Del Giudice F, Mogni M, Maffei M, Iolascon A, Forni GL, and Andolfo I
- Subjects
- Humans, Erythrocytes, Heterozygote, Phenotype, Ion Channels genetics, beta-Thalassemia genetics
- Abstract
Workflow of the study with some examples of the achieved results., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
16. Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients.
- Author
-
Bordoni V, Casale M, Pinto VM, Carsetti R, Gianesin B, Gamberini MR, Mazdai L, Barella S, Denotti AR, Colavita F, Perrotta S, Maggio A, Pitrolo L, Quintino S, Caminati M, Mazzi F, Ceolan J, De Franceschi L, Forni GL, Locatelli F, and Agrati C
- Subjects
- Humans, Blood Transfusion, RNA, Messenger, Vaccination, Antibodies, Viral, Immunity, Humoral, COVID-19 prevention & control, beta-Thalassemia genetics, beta-Thalassemia therapy
- Published
- 2023
- Full Text
- View/download PDF
17. Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy.
- Author
-
Romano N, Baiardi G, Pinto VM, Quintino S, Gianesin B, Sasso R, Diociasi A, Mattioli F, Marchese R, Abbruzzese G, Castaldi A, and Forni GL
- Abstract
Neurodegeneration with brain iron accumulation (NBIA) comprises various rare clinical entities with brain iron overload as a common feature. Magnetic resonance imaging (MRI) allows diagnosis of this condition, and genetic molecular testing can confirm the diagnosis to better understand the intracellular damage mechanism involved. NBIA groups disorders include: pantothenate kinase-associated neurodegeneration (PKAN), mutations in the gene encoding pantothenate kinase 2 (PANK2); neuroferritinopathy, mutations in the calcium-independent phospholipase A2 gene (PLA2G6); aceruloplasminemia; and other subtypes with no specific clinical or MRI specific patterns identified. There is no causal therapy, and only symptom treatments are available for this condition. Promising strategies include the use of deferiprone (DFP), an orally administered bidentate iron chelator with the ability to pass through the blood-brain barrier. This is a prospective study analysis with a mean follow-up time of 5.5 ± 2.3 years (min-max: 2.4-9.6 years) to define DFP (15 mg/kg bid)'s efficacy and safety in the continuous treatment of 10 NBIA patients through clinical and neuroradiological evaluation. Our results show the progressive decrease in the cerebral accumulation of iron evaluated by MRI and a substantial stability of the overall clinical neurological picture without a significant correlation between clinical and radiological findings. Complete ferrochelation throughout the day appears to be of fundamental importance considering that oxidative damage is generated, above, all by non-transferrin-bound iron (NTBI); thus, we hypothesize that a (TID) administration regimen of DFP might better apply its chelating properties over 24 h with the aim to also obtain clinical improvement beyond the neuroradiological improvement.
- Published
- 2022
- Full Text
- View/download PDF
18. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.
- Author
-
Longo F, Gianesin B, Voi V, Motta I, Pinto VM, Piolatto A, Spasiano A, Ruffo GB, Gamberini MR, Barella S, Mariani R, Fidone C, Rosso R, Casale M, Roberti D, Dal Zotto C, Vitucci A, Bonetti F, Pitrolo L, Quaresima M, Ribersani M, Quota A, Arcioni F, Campisi S, Massa A, De Michele E, Lisi R, Miano M, Bagnato S, Gentile M, Carrai V, Putti MC, Serra M, Gaglioti C, Migone De Amicis M, Graziadei G, De Giovanni A, Ricchi P, Balocco M, Quintino S, Borsellino Z, Fortini M, Denotti AR, Tartaglione I, Beccaria A, Marziali M, Maggio A, Perrotta S, Piperno A, Filosa A, Cappellini MD, De Franceschi L, Piga A, and Forni GL
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, COVID-19 epidemiology, COVID-19 mortality, Female, Hemoglobinopathies epidemiology, Hemoglobinopathies mortality, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Risk Factors, SARS-CoV-2 isolation & purification, Thalassemia complications, Thalassemia epidemiology, Thalassemia mortality, Young Adult, COVID-19 complications, Hemoglobinopathies complications
- Published
- 2022
- Full Text
- View/download PDF
19. Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values.
- Author
-
Gianesin B, Pinto VM, Casale M, Corti P, Fidone C, Quintino S, Voi V, and Forni GL
- Subjects
- Adult, Anemia, Sickle Cell epidemiology, Blood Volume Determination methods, Erythrocyte Transfusion methods, Female, Humans, Italy epidemiology, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Young Adult, Anemia, Sickle Cell blood, Anemia, Sickle Cell therapy, Blood Volume physiology, Blood Volume Determination standards, Erythrocyte Transfusion standards, Hemoglobin, Sickle metabolism
- Abstract
Manual erythroexchange (MEEX) was proven to be effective and safe in the management of sickle cell disease (SCD). The goal is to quickly reduce the percentage of hemoglobin S (HbS%). A national survey of the Italian Society for Thalassemia and Hemoglobinopathies (SITE) observed a great variability among MEEX protocols none of which were found to be predictive of the values of HbS% and hemoglobin (Hb) after the exchange. Two equations to estimate the HbS% and Hb values to be obtained after MEEX were developed based on the results of the MEEX procedures in place in the centers participating in the present study. A standard protocol was subsequently defined to evaluate the volumes to exchange to obtain the target values of HbS% and Hb. The protocol was tested in 261 MEEX performed in SCD patients followed in the 5 participating centers that belong to the Italian Hemoglobinopathy Comprehensive Care Network, with the support of the SITE. The results showed a correlation between the estimated and measured values of HbS% and Hb (R
p 0.95 and 0.65 respectively, p < 0.001). A negligible bias was found for the prediction of HbS% and a bias of 1 g/dl for Hb. From consecutive MEEX, a rate of increase of HbS% between two exchanges of around 0.4% per day (p < 0.001) was measured. This protocol was shown to be effective and safe, as all patients reached the target value of HbS%. All the MEEX procedures were carried out with single venous access. No adverse events or reactions such as hypotension or electrolyte imbalance were reported nor were any complaints concerning the procedures received from patients.- Published
- 2020
- Full Text
- View/download PDF
20. Sickle cell disease: a review for the internist.
- Author
-
Pinto VM, Balocco M, Quintino S, and Forni GL
- Subjects
- Disease Management, Humans, Internal Medicine methods, Internal Medicine trends, Anemia, Sickle Cell complications, Anemia, Sickle Cell physiopathology, Anemia, Sickle Cell therapy
- Abstract
Sickle cell disease (SCD) is the most important hemoglobinopathy worldwide in terms of frequency and social impact, recently recognized as a global public health problem by the World Health Organization. It is a monogenic but multisystem disorder with high morbidity and mortality. Vaso-occlusion, hemolytic anemia and vasculopathy are the hallmarks of SCD pathophysiology. This review focuses both on "time-dependent" acute clinical manifestations of SCD and chronic complications commonly described in adults with SCD. The review covers a broad spectrum of topics concerning current management of SCD targeted at the internists and emergency specialists who are increasingly involved in the care of acute and chronic complications of SCD patients.
- Published
- 2019
- Full Text
- View/download PDF
21. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
- Author
-
Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, De Franceschi L, and Forni GL
- Subjects
- Adolescent, Adult, Deferasirox therapeutic use, Deferiprone therapeutic use, Drug Administration Schedule, Drug Synergism, Female, Follow-Up Studies, Humans, Iron Chelating Agents therapeutic use, Iron Overload etiology, Iron Overload prevention & control, Male, Thalassemia complications, Young Adult, Blood Transfusion, Chelation Therapy methods, Deferasirox administration & dosage, Deferiprone administration & dosage, Iron metabolism, Iron Chelating Agents administration & dosage, Iron Overload drug therapy, Thalassemia therapy
- Published
- 2018
- Full Text
- View/download PDF
22. Characterization of ferromagnetic or conductive properties of metallic foreign objects embedded within the human body with magnetic iron detector (MID): Screening patients for MRI.
- Author
-
Gianesin B, Zefiro D, Paparo F, Caminata A, Balocco M, Carrara P, Quintino S, Pinto V, Bacigalupo L, Rollandi GA, Marinelli M, and Forni GL
- Subjects
- Adult, Aged, Contraindications, Female, Humans, Iron Overload diagnosis, Male, Middle Aged, Patient Safety, Sensitivity and Specificity, Foreign Bodies diagnosis, Iron, Magnetic Fields, Magnetic Resonance Imaging methods, Magnetometry instrumentation, Magnetometry methods, Magnets, Mass Screening, Metals, Prostheses and Implants
- Abstract
Purpose: A preliminary assessment of the MRI-compatibility of metallic object possibly embedded within the patient is required before conducting the MRI examination. The Magnetic Iron Detector (MID) is a highly sensitive susceptometer that uses a weak magnetic field to measure iron overload in the liver. MID might be used to perform a screening procedure for MRI by determining the ferromagnetic/conductive properties of embedded metallic objects., Methods: The study was composed by: (i) definition of MID sensitivity threshold; (ii) application of MID in a procedure to characterize the ferromagnetic/conductive properties of metallic foreign objects in 958 patients scheduled for MID examination., Results: The detection threshold for ferromagnetic objects was found to be the equivalent of a piece of wire of length 2 mm and gauge 0.8 mm(2) and, representing purely conductive objects, an aluminum sheet of area 2 × 2 cm(2) . Of 958 patients, 165 had foreign bodies of unknown nature. MID was able to detect those with ferromagnetic and/or conducting properties based on fluctuations in the magnetic and eddy current signals versus control., Conclusion: The high sensitivity of MID makes it suitable for assessing the ferromagnetic/conductive properties of metallic foreign objects embedded within the body of patients scheduled for MRI., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
23. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
- Author
-
Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, Gobbi M, Frassoni F, and Sessarego M
- Subjects
- Adult, Aged, Benzamides, Bone Marrow metabolism, Bone Marrow pathology, Chromosome Banding, Cytogenetic Analysis, Drug Resistance, Neoplasm, Humans, Imatinib Mesylate, In Situ Hybridization, Fluorescence, Interferon-alpha adverse effects, Interphase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Metaphase, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Protein-Tyrosine Kinases antagonists & inhibitors, Salvage Therapy, Survival Rate, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Neoplasm, Residual diagnosis, Piperazines therapeutic use, Pyrimidines therapeutic use
- Abstract
Imatinib mesylate determines a favorable clinical course in most Ph positive Chronic Myeloid Leukemia (CML) patients in the chronic phase. Cytogenetic response is usually evaluated by analyzing 20-25 bone marrow metaphases using standard banding techniques. Since this methodology has very low sensitivity, we compared the results obtained by standard banding techniques to the ones obtained by fluorescent in situ hybridization (FISH). This was also done to identify any possible discrepancies between the two techniques. We analyzed 40 Ph+ CML patients in the chronic phase who had previously been treated with interferon alpha (IFNalpha) and who were receiving imatinib. The studies were performed by utilizing the same BM cell samples fixed in acetic acid/methanol, before imatinib therapy and then quarterly. Comparison of cytogenetic results to FISH results at 3 and 6 months of imatinib treatment showed that some patients who had achieved major cytogenetic response (i.e.<35% of examined metaphases showing Ph), showed retention of a higher number of persisting Ph+ cells when examined by FISH, and they did not achieve major FISH response (i.e. <35% of examined interphase cells show the BCR-ABL fusion signal). The discrepancy we found between the results that were obtained by analyzing metaphases and interphase cells disappeared in the subsequent examinations. Moreover, we found that 4 patients (10%) were still Ph+ in all the metaphases we examined even though they achieved excellent clinical response. On the basis of this small series of patients, we suggest that cytogenetic evaluation of patients on imatinib therapy should be performed by utilizing the classic banding technique (metaphase examination), but also by using the FISH technique (interphase examination), since the two methodologies may provide different results.
- Published
- 2004
24. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
- Author
-
Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, and Gobbi M
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Combined Modality Therapy, Cytarabine administration & dosage, Female, Granulocyte Colony-Stimulating Factor adverse effects, Humans, Idarubicin administration & dosage, Karyotyping, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics, Patient Selection, Recombinant Proteins, Retrospective Studies, Survival Analysis, Treatment Outcome, Vidarabine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Granulocyte Colony-Stimulating Factor therapeutic use, Leukemia, Myeloid, Acute therapy, Myelodysplastic Syndromes therapy, Stem Cell Transplantation, Vidarabine analogs & derivatives
- Abstract
Forty-three consecutive patients with de novo and untreated non M3 AML aged 60 or less entered the study. The mean age of patients was 50 (range 15-60). The induction regimen (FLAG-Ida) included fludarabine (30 mg/sqm), Ara-C (2 g/sqm) on days 1-5, and idarubicin (10 mg/sqm) on days 1, 3, 5. G-CSF (300 mcg/day) was administered s.c. 12 hours before starting fludarabine and was continued for five days. HDT with stem cell rescue was planned for all patients in first CR after one course of high dose Ara-C (HDAC) consolidation and in good clinical conditions. Forty-two (98%) patients were evaluable for response. One patient died during induction (2%). CR was achieved in 35 patients (82%). Twenty-three patients, 66% of those achieving CR, underwent autologous (N = 17) or allogeneic (N = 6) transplantation. With a median follow up of 24 months, the average median duration of CR is 17 months (range 3-66) and the median survival is 20 months (range 1-83). Overall the 5 year projected disease free survival (DFS) and overall survival (OS) were 37% and 43%, respectively. Among patients who underwent stem cell transplantation DFS and OS were 53% and 69%, respectively. The median time to PMN recovery (> 0.5 x 10(9)/l) was 17 days (range 10-28) and 50 x 10(9)/l platelets were reached at a median of 17 days (12-38). In conclusion FLAG-Ida regimen is effective, low toxic and improves feasibility of stem cell transplant.
- Published
- 2002
25. Thalidomide in agnogenic and secondary myelofibrosis.
- Author
-
Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M, Miglino M, Pierri I, and Gobbi M
- Subjects
- Adult, Aged, Angiogenesis Inhibitors adverse effects, Female, Follow-Up Studies, Hemoglobins metabolism, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Primary Myelofibrosis blood, Primary Myelofibrosis complications, Thalidomide adverse effects, Treatment Outcome, Angiogenesis Inhibitors therapeutic use, Immunosuppressive Agents therapeutic use, Primary Myelofibrosis drug therapy, Thalidomide therapeutic use
- Abstract
Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.
- Published
- 2001
- Full Text
- View/download PDF
26. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
- Author
-
Clavio M, Quintino S, Venturino C, Ballerini F, Varaldo R, Gatto S, Galbusera V, Garrone A, Grasso R, Canepa L, Miglino M, Pierri I, and Gobbi M
- Subjects
- Antibodies, Monoclonal, Murine-Derived, B-Lymphocytes pathology, Diagnosis, Differential, Humans, Immunophenotyping, Immunotherapy, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Lymphoproliferative Disorders immunology, Rituximab, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Lymphoma, B-Cell therapy
- Abstract
Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells. The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma. The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma. t(9;14)(p13;q32) chromosomal translocation has been found in 50% of all LPL cases. The cytogenetic rearrangement juxtaposes the PAX-5 gene, which encodes for an essential transcription factor for B-cell proliferation and differention, to the Ig heavy chain gene. The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients. Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone. Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy. In a multicentric European trial Foran et al. administered the chimeric anti-CD20-monoclonal antibody (Rituximab) to 28 patients with previously treated IMC. Seven out of 25 evaluable patients (28%) achieved a partial response. Byrd et al. examined the outcome of 7 previously treated WM patients who received weekly infusions of rituximab (375 mg/m2). Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity. Partial responses were noted in three of these patients, including two with fludarabine-refractory disease. These data suggest that rituximab exerts clinical activity on heavily pre-treated patients with WM. Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab. Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas. In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.
- Published
- 2001
27. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
- Author
-
Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, Miglino M, Muner P, Damasio E, and Gobbi M
- Subjects
- Adolescent, Adult, Costs and Cost Analysis, Drug Synergism, Female, Humans, Leukemia, Myeloid, Acute drug therapy, Male, Maximum Tolerated Dose, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Vidarabine analogs & derivatives, Antineoplastic Agents economics, Antineoplastic Combined Chemotherapy Protocols economics, Cytarabine economics, Drug Costs, Granulocyte Colony-Stimulating Factor economics, Leukemia, Myeloid, Acute economics, Mitoxantrone economics, Vidarabine economics
- Abstract
Since the social and financial impact of AML therapy is becoming more and more relevant we analyzed the cost of induction therapy of two different regimens. The first one is part of the widely employed EORTC-GIMEMA AML-10 and consists often days of therapy. The second (FLANG) is a short (three day), Fludarabine, Ara-C, mitoxantrone and G-CSF containing regimen. We first retrospectively analyzed the outcome of 77 consecutive AML patients with comparable clinical and haematological features receiving FLANG (25) or AML-10 (52), between June 1993 and October 1999, and observed equivalent CR rate, as well as DFS and overall survival duration. We then selected 9 non pretreated patients per group who reached CR after one course of therapy. Patients treated with FLANG had a statistically significant earlier platelet recovery compared to those treated with AML-10, fewer days of intravenous antibiotic therapy (14/22, respectively, p < 0.05), and a shorter hospitalization period (22/33 days, p < 0.01). FLANG was significantly more expensive than AML 10 as far as the cost of antiblastic drugs (p < 0.01) and G-CSF support (p < 0.05) are concerned. On the contrary, the expense for antiemetic drugs (p < 0.01) and the cost of personnel and other services ($5,906/$3,970, p < 0.05) were higher for AML-10 than for FLANG. Overall, the average costs of FLANG and AML10 were $9,269 and $12,424 respectively (p < 0.05; difference = -25%). Our study seems to indicate that, compared to AML-10, FLANG induction is as effective, less expensive and it allows for a decrease in the length of hospitalization and thus for better exploitation of the financial resources of Hematology-Oncology departments.
- Published
- 2001
28. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
- Author
-
Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, and Gobbi M
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Cycle drug effects, Cytarabine administration & dosage, Disease-Free Survival, Drug Administration Schedule, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Idarubicin administration & dosage, Karyotyping, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Mitoxantrone administration & dosage, Prognosis, Survival Analysis, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
GM-IVA is a short and effective induction therapy of non M3 de novo AML including GM-CSF (300 mcg 12 hrs before starting therapy), Ara-C (250 mg/sqm c.i. x 3 days), VP16 (100 mg/sqm x 3 days) and idarubicin (12 mg/sqm x 3 days); it was followed by a fludarabine containing salvage protocol (FLANG). Patients <60 years of age achieving CR received 2 courses of FLANG and autologous or allogeneic BMT when possible. Patients >60 years of age in CR received a second course of GM-IVA. Twenty-one consecutive patients (mean age 64, range 29-85) entered the study. Three patients (14%) died during induction therapy. After one course of GM-IVA, CR was achieved in 12 patients (57%). Two further patients were salvaged with FLANG therapy so that the final CR rate was 14/21 (67%). In elderly patients the final CR rate (62%) is noteworthy, considering that 6 patients were >70 years of age and 3 were >80. All three patients >80 achieved CR (lasting 5 to 7 months). The median time of granulocyte and platelet recovery was 15 days. Our scheme was well tolerated. In the group of elderly patients 3 out of 14 died during induction (21%) and 4 life-threatening infections were observed (28%). The short duration of cytotoxic therapy and perhaps the use of G-CSF contributed to a reduction of the hospitalization period (median of 22 days), thus providing major savings on induction costs and allowing for better utilization of beds as well as significantly improving patients' quality of life.
- Published
- 1999
29. A few words about a new treatment for pink arteriosclerosis with short waves.
- Author
-
DA CONCEICAO QUINTINO S
- Subjects
- Diathermy, Hyperthermia, Induced
- Published
- 1948
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.